Pelthos Therapeutics Expands Formulary Coverage for ZELSUVMI Topical Gel

Pelthos Therapeutics has secured new formulary coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%, with a major Pharmacy Benefit Manager, extending reach to an additional 24 million covered lives. Additionally, enhanced commercial coverage was obtained through a regional commercial health plan, representing approximately 3 million covered lives.